ES2633618T3 - Formulaciones farmacéuticas de nitrito y sus usos - Google Patents

Info

Publication number

ES2633618T3

ES2633618T3 ES10824097.9T ES10824097T ES2633618T3 ES 2633618 T3 ES2633618 T3 ES 2633618T3 ES 10824097 T ES10824097 T ES 10824097T ES 2633618 T3 ES2633618 T3 ES 2633618T3

Authority

ES

Spain

Prior art keywords

nitrite

pharmaceutical composition

release

pharmaceutically acceptable

formulation

Prior art date

2009-10-14

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Active

Links

• Espacenet
• Global Dossier
• Discuss

• IOVCWXUNBOPUCH-UHFFFAOYSA-M Nitrite anion Chemical compound [O-]N=O IOVCWXUNBOPUCH-UHFFFAOYSA-M 0.000 title claims abstract description 93
• 239000000203 mixture Substances 0.000 title claims description 110
• 238000009472 formulation Methods 0.000 title claims description 52
• 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 61
• 239000000546 pharmaceutical excipient Substances 0.000 claims abstract description 35
• -1 nitrite ions Chemical class 0.000 claims abstract description 28
• 150000003839 salts Chemical class 0.000 claims abstract description 27
• 230000036470 plasma concentration Effects 0.000 claims abstract description 16
• 239000012453 solvate Substances 0.000 claims abstract description 16
• 238000013268 sustained release Methods 0.000 claims abstract description 4
• 239000012730 sustained-release form Substances 0.000 claims abstract description 4
• LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 claims description 54
• 238000000034 method Methods 0.000 claims description 49
• 230000001684 chronic effect Effects 0.000 claims description 32
• 208000028867 ischemia Diseases 0.000 claims description 30
• 235000010288 sodium nitrite Nutrition 0.000 claims description 27
• 229940005654 nitrite ion Drugs 0.000 claims description 16
• 210000002784 stomach Anatomy 0.000 claims description 13
• 230000003111 delayed effect Effects 0.000 claims description 11
• 235000010289 potassium nitrite Nutrition 0.000 claims description 7
• 230000006735 deficit Effects 0.000 claims description 5
• 239000011247 coating layer Substances 0.000 claims description 2
• 101000805606 Deinagkistrodon acutus Zinc metalloproteinase-disintegrin-like acurhagin Proteins 0.000 claims 1
• 241001122767 Theaceae Species 0.000 claims 1
• 230000001502 supplementing effect Effects 0.000 claims 1
• 210000001519 tissue Anatomy 0.000 description 53
• 239000003826 tablet Substances 0.000 description 52
• 238000000576 coating method Methods 0.000 description 37
• 150000001875 compounds Chemical class 0.000 description 28
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 28
• 239000003814 drug Substances 0.000 description 26
• 239000011248 coating agent Substances 0.000 description 25
• 229920000642 polymer Polymers 0.000 description 25
• 238000011282 treatment Methods 0.000 description 23
• 239000002775 capsule Substances 0.000 description 20
• 229940079593 drug Drugs 0.000 description 20
• URAYPUMNDPQOKB-UHFFFAOYSA-N triacetin Chemical compound CC(=O)OCC(OC(C)=O)COC(C)=O URAYPUMNDPQOKB-UHFFFAOYSA-N 0.000 description 20
• 239000008187 granular material Substances 0.000 description 19
• ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical group CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 18
• 201000010099 disease Diseases 0.000 description 18
• 239000001856 Ethyl cellulose Substances 0.000 description 17
• 238000013270 controlled release Methods 0.000 description 17
• 235000019325 ethyl cellulose Nutrition 0.000 description 17
• 229920001249 ethyl cellulose Polymers 0.000 description 17
• 239000000651 prodrug Substances 0.000 description 17
• 229940002612 prodrug Drugs 0.000 description 17
• 239000008188 pellet Substances 0.000 description 13
• LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 12
• 239000004480 active ingredient Substances 0.000 description 12
• 230000006835 compression Effects 0.000 description 12
• 239000000243 solution Substances 0.000 description 12
• 208000024891 symptom Diseases 0.000 description 12
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 12
• 238000007906 compression Methods 0.000 description 11
• 229920000623 Cellulose acetate phthalate Polymers 0.000 description 10
• MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 10
• 229940081734 cellulose acetate phthalate Drugs 0.000 description 10
• 208000035475 disorder Diseases 0.000 description 10
• 239000002552 dosage form Substances 0.000 description 10
• 239000001087 glyceryl triacetate Substances 0.000 description 10
• 235000013773 glyceryl triacetate Nutrition 0.000 description 10
• 208000014674 injury Diseases 0.000 description 10
• 150000002826 nitrites Chemical class 0.000 description 10
• 239000000843 powder Substances 0.000 description 10
• 239000002904 solvent Substances 0.000 description 10
• 229960002622 triacetin Drugs 0.000 description 10
• NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 9
• 210000004204 blood vessel Anatomy 0.000 description 9
• 238000009505 enteric coating Methods 0.000 description 9
• 239000002702 enteric coating Substances 0.000 description 9
• 230000000302 ischemic effect Effects 0.000 description 9
• 239000007787 solid Substances 0.000 description 9
• VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 8
• LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 8
• HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 8
• 238000012360 testing method Methods 0.000 description 8
• WCOXQTXVACYMLM-UHFFFAOYSA-N 2,3-bis(12-hydroxyoctadecanoyloxy)propyl 12-hydroxyoctadecanoate Chemical compound CCCCCCC(O)CCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCC(O)CCCCCC)COC(=O)CCCCCCCCCCC(O)CCCCCC WCOXQTXVACYMLM-UHFFFAOYSA-N 0.000 description 7
• 229920000168 Microcrystalline cellulose Polymers 0.000 description 7
• 229910002651 NO3 Inorganic materials 0.000 description 7
• 208000005764 Peripheral Arterial Disease Diseases 0.000 description 7
• 208000030831 Peripheral arterial occlusive disease Diseases 0.000 description 7
• 230000033115 angiogenesis Effects 0.000 description 7
• 229920002988 biodegradable polymer Polymers 0.000 description 7
• 239000004621 biodegradable polymer Substances 0.000 description 7
• 230000015572 biosynthetic process Effects 0.000 description 7
• 230000017531 blood circulation Effects 0.000 description 7
• 235000010980 cellulose Nutrition 0.000 description 7
• 229920002678 cellulose Polymers 0.000 description 7
• 239000001913 cellulose Substances 0.000 description 7
• 239000003795 chemical substances by application Substances 0.000 description 7
• 210000001072 colon Anatomy 0.000 description 7
• 235000019813 microcrystalline cellulose Nutrition 0.000 description 7
• 239000008108 microcrystalline cellulose Substances 0.000 description 7
• 229940016286 microcrystalline cellulose Drugs 0.000 description 7
• GQPLMRYTRLFLPF-UHFFFAOYSA-N nitrous oxide Inorganic materials [O-][N+]#N GQPLMRYTRLFLPF-UHFFFAOYSA-N 0.000 description 7
• WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
• 229920001800 Shellac Polymers 0.000 description 6
• 235000010443 alginic acid Nutrition 0.000 description 6
• 229920000615 alginic acid Polymers 0.000 description 6
• 210000001367 artery Anatomy 0.000 description 6
• 210000002808 connective tissue Anatomy 0.000 description 6
• 230000007423 decrease Effects 0.000 description 6
• 206010012601 diabetes mellitus Diseases 0.000 description 6
• 238000004090 dissolution Methods 0.000 description 6
• 230000012010 growth Effects 0.000 description 6
• 208000027866 inflammatory disease Diseases 0.000 description 6
• 229920000609 methyl cellulose Polymers 0.000 description 6
• 235000010981 methylcellulose Nutrition 0.000 description 6
• 239000001923 methylcellulose Substances 0.000 description 6
• 150000002823 nitrates Chemical class 0.000 description 6
• 229920001223 polyethylene glycol Polymers 0.000 description 6
• 230000008569 process Effects 0.000 description 6
• 230000002035 prolonged effect Effects 0.000 description 6
• 235000013874 shellac Nutrition 0.000 description 6
• 239000004208 shellac Substances 0.000 description 6
• ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 6
• 229940113147 shellac Drugs 0.000 description 6
• 239000000126 substance Substances 0.000 description 6
• 230000001225 therapeutic effect Effects 0.000 description 6
• 230000008733 trauma Effects 0.000 description 6
• 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 5
• 241001465754 Metazoa Species 0.000 description 5
• 241000283973 Oryctolagus cuniculus Species 0.000 description 5
• VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 5
• FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
• 229920002472 Starch Polymers 0.000 description 5
• 208000027418 Wounds and injury Diseases 0.000 description 5
• 229910052784 alkaline earth metal Inorganic materials 0.000 description 5
• 230000027746 artery morphogenesis Effects 0.000 description 5
• 239000003153 chemical reaction reagent Substances 0.000 description 5
• 230000006378 damage Effects 0.000 description 5
• 239000003085 diluting agent Substances 0.000 description 5
• 230000002526 effect on cardiovascular system Effects 0.000 description 5
• 239000000945 filler Substances 0.000 description 5
• 230000002496 gastric effect Effects 0.000 description 5
• 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 5
• 239000001863 hydroxypropyl cellulose Substances 0.000 description 5
• 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 5
• 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 5
• 239000004615 ingredient Substances 0.000 description 5
• 239000010410 layer Substances 0.000 description 5
• 239000011159 matrix material Substances 0.000 description 5
• 210000000056 organ Anatomy 0.000 description 5
• 239000004014 plasticizer Substances 0.000 description 5
• 230000009467 reduction Effects 0.000 description 5
• 239000011734 sodium Substances 0.000 description 5
• 239000001509 sodium citrate Substances 0.000 description 5
• NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 5
• 235000011083 sodium citrates Nutrition 0.000 description 5
• 235000019698 starch Nutrition 0.000 description 5
• 238000001356 surgical procedure Methods 0.000 description 5
• 239000003981 vehicle Substances 0.000 description 5
• VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 4
• 208000004476 Acute Coronary Syndrome Diseases 0.000 description 4
• CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
• FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 4
• IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
• DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 4
• 208000022559 Inflammatory bowel disease Diseases 0.000 description 4
• 206010022562 Intermittent claudication Diseases 0.000 description 4
• SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 4
• IOVCWXUNBOPUCH-UHFFFAOYSA-N Nitrous acid Chemical class ON=O IOVCWXUNBOPUCH-UHFFFAOYSA-N 0.000 description 4
• 239000002202 Polyethylene glycol Substances 0.000 description 4
• 229930006000 Sucrose Natural products 0.000 description 4
• CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 4
• 206010052428 Wound Diseases 0.000 description 4
• 239000002253 acid Substances 0.000 description 4
• 230000008901 benefit Effects 0.000 description 4
• 210000000988 bone and bone Anatomy 0.000 description 4
• 229910000019 calcium carbonate Inorganic materials 0.000 description 4
• 239000003937 drug carrier Substances 0.000 description 4
• 210000000981 epithelium Anatomy 0.000 description 4
• 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 4
• UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 4
• 239000000314 lubricant Substances 0.000 description 4
• 235000019359 magnesium stearate Nutrition 0.000 description 4
• 239000000463 material Substances 0.000 description 4
• GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 4
• QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 4
• 239000006186 oral dosage form Substances 0.000 description 4
• 230000036961 partial effect Effects 0.000 description 4
• 239000002245 particle Substances 0.000 description 4
• 208000033808 peripheral neuropathy Diseases 0.000 description 4
• 229920000036 polyvinylpyrrolidone Polymers 0.000 description 4
• 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 4
• 235000015424 sodium Nutrition 0.000 description 4
• 229910052708 sodium Inorganic materials 0.000 description 4
• 235000010356 sorbitol Nutrition 0.000 description 4
• 239000000600 sorbitol Substances 0.000 description 4
• 239000005720 sucrose Substances 0.000 description 4
• 239000007916 tablet composition Substances 0.000 description 4
• 229940124597 therapeutic agent Drugs 0.000 description 4
• 230000002792 vascular Effects 0.000 description 4
• QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 3
• 239000004475 Arginine Substances 0.000 description 3
• 201000001320 Atherosclerosis Diseases 0.000 description 3
• 208000023275 Autoimmune disease Diseases 0.000 description 3
• 208000010392 Bone Fractures Diseases 0.000 description 3
• 208000024172 Cardiovascular disease Diseases 0.000 description 3
• FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 3
• FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 3
• YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
• XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
• 108010010803 Gelatin Proteins 0.000 description 3
• PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
• 206010021143 Hypoxia Diseases 0.000 description 3
• GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
• 229930195725 Mannitol Natural products 0.000 description 3
• ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
• WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 3
• 208000002193 Pain Diseases 0.000 description 3
• DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
• 235000021355 Stearic acid Nutrition 0.000 description 3
• 208000006011 Stroke Diseases 0.000 description 3
• ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
• 238000013459 approach Methods 0.000 description 3
• ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 3
• 230000009286 beneficial effect Effects 0.000 description 3
• 230000036770 blood supply Effects 0.000 description 3
• 239000011575 calcium Substances 0.000 description 3
• 239000001506 calcium phosphate Substances 0.000 description 3
• 229910000389 calcium phosphate Inorganic materials 0.000 description 3
• 235000011010 calcium phosphates Nutrition 0.000 description 3
• 239000007963 capsule composition Substances 0.000 description 3
• 229920006217 cellulose acetate butyrate Polymers 0.000 description 3
• KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
• 230000000875 corresponding effect Effects 0.000 description 3
• 230000007547 defect Effects 0.000 description 3
• 235000015872 dietary supplement Nutrition 0.000 description 3
• 239000006185 dispersion Substances 0.000 description 3
• 239000000839 emulsion Substances 0.000 description 3
• 210000002889 endothelial cell Anatomy 0.000 description 3
• 230000007613 environmental effect Effects 0.000 description 3
• 210000003414 extremity Anatomy 0.000 description 3
• 239000013022 formulation composition Substances 0.000 description 3
• 239000008273 gelatin Substances 0.000 description 3
• 229920000159 gelatin Polymers 0.000 description 3
• 229940014259 gelatin Drugs 0.000 description 3
• 239000007903 gelatin capsule Substances 0.000 description 3
• 235000019322 gelatine Nutrition 0.000 description 3
• 235000011852 gelatine desserts Nutrition 0.000 description 3
• WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 3
• 239000012729 immediate-release (IR) formulation Substances 0.000 description 3
• 238000007654 immersion Methods 0.000 description 3
• 238000001727 in vivo Methods 0.000 description 3
• 230000002757 inflammatory effect Effects 0.000 description 3
• 208000021156 intermittent vascular claudication Diseases 0.000 description 3
• 238000001990 intravenous administration Methods 0.000 description 3
• 239000008101 lactose Substances 0.000 description 3
• 239000011777 magnesium Substances 0.000 description 3
• 239000000594 mannitol Substances 0.000 description 3
• 235000010355 mannitol Nutrition 0.000 description 3
• 239000011859 microparticle Substances 0.000 description 3
• 238000002156 mixing Methods 0.000 description 3
• 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 3
• 210000003205 muscle Anatomy 0.000 description 3
• 208000010125 myocardial infarction Diseases 0.000 description 3
• 239000001272 nitrous oxide Substances 0.000 description 3
• OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 3
• 230000002085 persistent effect Effects 0.000 description 3
• 229940124531 pharmaceutical excipient Drugs 0.000 description 3
• 239000001267 polyvinylpyrrolidone Substances 0.000 description 3
• 229920001592 potato starch Polymers 0.000 description 3
• 238000002360 preparation method Methods 0.000 description 3
• 239000003755 preservative agent Substances 0.000 description 3
• 210000000813 small intestine Anatomy 0.000 description 3
• 235000017281 sodium acetate Nutrition 0.000 description 3
• 239000008117 stearic acid Substances 0.000 description 3
• 239000013589 supplement Substances 0.000 description 3
• 239000000725 suspension Substances 0.000 description 3
• 235000020357 syrup Nutrition 0.000 description 3
• 239000006188 syrup Substances 0.000 description 3
• 239000000454 talc Substances 0.000 description 3
• 229910052623 talc Inorganic materials 0.000 description 3
• 235000012222 talc Nutrition 0.000 description 3
• 230000008736 traumatic injury Effects 0.000 description 3
• QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 3
• LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 2
• GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
• CYSGHNMQYZDMIA-UHFFFAOYSA-N 1,3-Dimethyl-2-imidazolidinon Chemical compound CN1CCN(C)C1=O CYSGHNMQYZDMIA-UHFFFAOYSA-N 0.000 description 2
• IZHVBANLECCAGF-UHFFFAOYSA-N 2-hydroxy-3-(octadecanoyloxy)propyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)COC(=O)CCCCCCCCCCCCCCCCC IZHVBANLECCAGF-UHFFFAOYSA-N 0.000 description 2
• FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 2
• GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
• QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 2
• 206010003210 Arteriosclerosis Diseases 0.000 description 2
• IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
• 239000005552 B01AC04 - Clopidogrel Substances 0.000 description 2
• 239000004322 Butylated hydroxytoluene Substances 0.000 description 2
• NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 2
• OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
• 229920002284 Cellulose triacetate Polymers 0.000 description 2
• HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
• 206010010356 Congenital anomaly Diseases 0.000 description 2
• 208000034656 Contusions Diseases 0.000 description 2
• 229920002785 Croscarmellose sodium Polymers 0.000 description 2
• 229920002307 Dextran Polymers 0.000 description 2
• ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 2
• 102000004190 Enzymes Human genes 0.000 description 2
• 108090000790 Enzymes Proteins 0.000 description 2
• QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 2
• 229920003136 Eudragit® L polymer Polymers 0.000 description 2
• 229920003137 Eudragit® S polymer Polymers 0.000 description 2
• 229920003134 Eudragit® polymer Polymers 0.000 description 2
• 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 2
• 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 2
• WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
• AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
• 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 2
• 206010019909 Hernia Diseases 0.000 description 2
• 208000034693 Laceration Diseases 0.000 description 2
• JVTAAEKCZFNVCJ-UHFFFAOYSA-N Lactic Acid Natural products CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
• FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
• 208000002720 Malnutrition Diseases 0.000 description 2
• 241000124008 Mammalia Species 0.000 description 2
• BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
• 229920000881 Modified starch Polymers 0.000 description 2
• 208000007101 Muscle Cramp Diseases 0.000 description 2
• FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 2
• 206010028980 Neoplasm Diseases 0.000 description 2
• 206010031252 Osteomyelitis Diseases 0.000 description 2
• 235000019483 Peanut oil Nutrition 0.000 description 2
• 208000037581 Persistent Infection Diseases 0.000 description 2
• 239000004698 Polyethylene Substances 0.000 description 2
• 229920001030 Polyethylene Glycol 4000 Polymers 0.000 description 2
• ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
• VYGQUTWHTHXGQB-FFHKNEKCSA-N Retinol Palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C VYGQUTWHTHXGQB-FFHKNEKCSA-N 0.000 description 2
• VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 2
• UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
• GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
• 206010052779 Transplant rejections Diseases 0.000 description 2
• AZFNGPAYDKGCRB-XCPIVNJJSA-M [(1s,2s)-2-amino-1,2-diphenylethyl]-(4-methylphenyl)sulfonylazanide;chlororuthenium(1+);1-methyl-4-propan-2-ylbenzene Chemical compound [Ru+]Cl.CC(C)C1=CC=C(C)C=C1.C1=CC(C)=CC=C1S(=O)(=O)[N-][C@@H](C=1C=CC=CC=1)[C@@H](N)C1=CC=CC=C1 AZFNGPAYDKGCRB-XCPIVNJJSA-M 0.000 description 2
• NNLVGZFZQQXQNW-ADJNRHBOSA-N [(2r,3r,4s,5r,6s)-4,5-diacetyloxy-3-[(2s,3r,4s,5r,6r)-3,4,5-triacetyloxy-6-(acetyloxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6s)-4,5,6-triacetyloxy-2-(acetyloxymethyl)oxan-3-yl]oxyoxan-2-yl]methyl acetate Chemical compound O([C@@H]1O[C@@H]([C@H]([C@H](OC(C)=O)[C@H]1OC(C)=O)O[C@H]1[C@@H]([C@@H](OC(C)=O)[C@H](OC(C)=O)[C@@H](COC(C)=O)O1)OC(C)=O)COC(=O)C)[C@@H]1[C@@H](COC(C)=O)O[C@@H](OC(C)=O)[C@H](OC(C)=O)[C@H]1OC(C)=O NNLVGZFZQQXQNW-ADJNRHBOSA-N 0.000 description 2
• DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
• GAMPNQJDUFQVQO-UHFFFAOYSA-N acetic acid;phthalic acid Chemical compound CC(O)=O.OC(=O)C1=CC=CC=C1C(O)=O GAMPNQJDUFQVQO-UHFFFAOYSA-N 0.000 description 2
• 239000008186 active pharmaceutical agent Substances 0.000 description 2
• 230000001154 acute effect Effects 0.000 description 2
• 229940072056 alginate Drugs 0.000 description 2
• 239000000783 alginic acid Substances 0.000 description 2
• 229960001126 alginic acid Drugs 0.000 description 2
• 150000004781 alginic acids Chemical class 0.000 description 2
• 239000003513 alkali Substances 0.000 description 2
• 150000001342 alkaline earth metals Chemical class 0.000 description 2
• 150000001412 amines Chemical class 0.000 description 2
• 238000002583 angiography Methods 0.000 description 2
• 239000002220 antihypertensive agent Substances 0.000 description 2
• 229940030600 antihypertensive agent Drugs 0.000 description 2
• 239000007864 aqueous solution Substances 0.000 description 2
• 235000009697 arginine Nutrition 0.000 description 2
• GJTDJAPHKDIQIQ-UHFFFAOYSA-L barium(2+);dinitrite Chemical compound [Ba+2].[O-]N=O.[O-]N=O GJTDJAPHKDIQIQ-UHFFFAOYSA-L 0.000 description 2
• SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
• WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
• 239000011230 binding agent Substances 0.000 description 2
• 235000010354 butylated hydroxytoluene Nutrition 0.000 description 2
• 229940095259 butylated hydroxytoluene Drugs 0.000 description 2
• 235000001465 calcium Nutrition 0.000 description 2
• 229910052791 calcium Inorganic materials 0.000 description 2
• OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
• 201000011510 cancer Diseases 0.000 description 2
• 239000001768 carboxy methyl cellulose Substances 0.000 description 2
• 239000004203 carnauba wax Substances 0.000 description 2
• 235000013869 carnauba wax Nutrition 0.000 description 2
• 229920002301 cellulose acetate Polymers 0.000 description 2
• 238000006243 chemical reaction Methods 0.000 description 2
• GKTWGGQPFAXNFI-HNNXBMFYSA-N clopidogrel Chemical compound C1([C@H](N2CC=3C=CSC=3CC2)C(=O)OC)=CC=CC=C1Cl GKTWGGQPFAXNFI-HNNXBMFYSA-N 0.000 description 2
• 229960003009 clopidogrel Drugs 0.000 description 2
• 239000000701 coagulant Substances 0.000 description 2
• 208000028831 congenital heart disease Diseases 0.000 description 2
• 229920001577 copolymer Polymers 0.000 description 2
• 230000003247 decreasing effect Effects 0.000 description 2
• 230000007812 deficiency Effects 0.000 description 2
• 230000002950 deficient Effects 0.000 description 2
• 238000011161 development Methods 0.000 description 2
• 230000018109 developmental process Effects 0.000 description 2
• 238000002405 diagnostic procedure Methods 0.000 description 2
• 235000014113 dietary fatty acids Nutrition 0.000 description 2
• 238000009792 diffusion process Methods 0.000 description 2
• 239000012153 distilled water Substances 0.000 description 2
• MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical compound CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 2
• 229940043264 dodecyl sulfate Drugs 0.000 description 2
• 229940088679 drug related substance Drugs 0.000 description 2
• 230000000694 effects Effects 0.000 description 2
• 239000003995 emulsifying agent Substances 0.000 description 2
• 239000012055 enteric layer Substances 0.000 description 2
• 210000002744 extracellular matrix Anatomy 0.000 description 2
• 206010016256 fatigue Diseases 0.000 description 2
• 239000000194 fatty acid Substances 0.000 description 2
• 229930195729 fatty acid Natural products 0.000 description 2
• 150000004665 fatty acids Chemical class 0.000 description 2
• 239000000796 flavoring agent Substances 0.000 description 2
• 239000012530 fluid Substances 0.000 description 2
• 235000013355 food flavoring agent Nutrition 0.000 description 2
• 235000003599 food sweetener Nutrition 0.000 description 2
• 210000002683 foot Anatomy 0.000 description 2
• 239000000499 gel Substances 0.000 description 2
• 125000003976 glyceryl group Chemical group [H]C([*])([H])C(O[H])([H])C(O[H])([H])[H] 0.000 description 2
• 229940075507 glyceryl monostearate Drugs 0.000 description 2
• 238000010438 heat treatment Methods 0.000 description 2
• IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 2
• 239000008240 homogeneous mixture Substances 0.000 description 2
• 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 2
• 229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 description 2
• 229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 description 2
• 230000007954 hypoxia Effects 0.000 description 2
• 230000000495 immunoinflammatory effect Effects 0.000 description 2
• 239000007943 implant Substances 0.000 description 2
• 230000006872 improvement Effects 0.000 description 2
• 208000015181 infectious disease Diseases 0.000 description 2
• 229910001959 inorganic nitrate Inorganic materials 0.000 description 2
• 208000023589 ischemic disease Diseases 0.000 description 2
• 210000002429 large intestine Anatomy 0.000 description 2
• 210000002414 leg Anatomy 0.000 description 2
• 150000002632 lipids Chemical class 0.000 description 2
• 239000007788 liquid Substances 0.000 description 2
• 230000033001 locomotion Effects 0.000 description 2
• 235000001055 magnesium Nutrition 0.000 description 2
• 229910052749 magnesium Inorganic materials 0.000 description 2
• 230000036244 malformation Effects 0.000 description 2
• LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
• 239000004005 microsphere Substances 0.000 description 2
• 208000031225 myocardial ischemia Diseases 0.000 description 2
• 210000004165 myocardium Anatomy 0.000 description 2
• GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 2
• 230000001537 neural effect Effects 0.000 description 2
• 231100000252 nontoxic Toxicity 0.000 description 2
• 230000003000 nontoxic effect Effects 0.000 description 2
• 235000018343 nutrient deficiency Nutrition 0.000 description 2
• 239000003921 oil Substances 0.000 description 2
• 235000019198 oils Nutrition 0.000 description 2
• 230000003204 osmotic effect Effects 0.000 description 2
• 206010033675 panniculitis Diseases 0.000 description 2
• 239000000312 peanut oil Substances 0.000 description 2
• 239000002304 perfume Substances 0.000 description 2
• 210000003668 pericyte Anatomy 0.000 description 2
• 230000000144 pharmacologic effect Effects 0.000 description 2
• RAFRTSDUWORDLA-UHFFFAOYSA-N phenyl 3-chloropropanoate Chemical compound ClCCC(=O)OC1=CC=CC=C1 RAFRTSDUWORDLA-UHFFFAOYSA-N 0.000 description 2
• 230000035479 physiological effects, processes and functions Effects 0.000 description 2
• 239000006187 pill Substances 0.000 description 2
• IUGYQRQAERSCNH-UHFFFAOYSA-M pivalate Chemical compound CC(C)(C)C([O-])=O IUGYQRQAERSCNH-UHFFFAOYSA-M 0.000 description 2
• 229920000573 polyethylene Polymers 0.000 description 2
• 229920000915 polyvinyl chloride Polymers 0.000 description 2
• 239000004800 polyvinyl chloride Substances 0.000 description 2
• 229910052700 potassium Inorganic materials 0.000 description 2
• 239000011591 potassium Substances 0.000 description 2
• 235000007686 potassium Nutrition 0.000 description 2
• 239000004304 potassium nitrite Substances 0.000 description 2
• 239000002243 precursor Substances 0.000 description 2
• 238000011321 prophylaxis Methods 0.000 description 2
• QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
• 230000010410 reperfusion Effects 0.000 description 2
• 230000004044 response Effects 0.000 description 2
• 239000000377 silicon dioxide Substances 0.000 description 2
• 235000012239 silicon dioxide Nutrition 0.000 description 2
• 210000002027 skeletal muscle Anatomy 0.000 description 2
• 210000002460 smooth muscle Anatomy 0.000 description 2
• 239000001632 sodium acetate Substances 0.000 description 2
• 239000011780 sodium chloride Substances 0.000 description 2
• 238000001694 spray drying Methods 0.000 description 2
• 239000008107 starch Substances 0.000 description 2
• 229940032147 starch Drugs 0.000 description 2
• 210000004304 subcutaneous tissue Anatomy 0.000 description 2
• 230000004083 survival effect Effects 0.000 description 2
• 239000000375 suspending agent Substances 0.000 description 2
• 239000003765 sweetening agent Substances 0.000 description 2
• 238000002560 therapeutic procedure Methods 0.000 description 2
• 230000017423 tissue regeneration Effects 0.000 description 2
• 231100000419 toxicity Toxicity 0.000 description 2
• 230000001988 toxicity Effects 0.000 description 2
• VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
• 238000002054 transplantation Methods 0.000 description 2
• GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
• 208000001072 type 2 diabetes mellitus Diseases 0.000 description 2
• 229920002554 vinyl polymer Polymers 0.000 description 2
• 230000029663 wound healing Effects 0.000 description 2
• ZOBPZXTWZATXDG-UHFFFAOYSA-N 1,3-thiazolidine-2,4-dione Chemical compound O=C1CSC(=O)N1 ZOBPZXTWZATXDG-UHFFFAOYSA-N 0.000 description 1
• RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
• JWYVGKFDLWWQJX-UHFFFAOYSA-N 1-ethenylazepan-2-one Chemical compound C=CN1CCCCCC1=O JWYVGKFDLWWQJX-UHFFFAOYSA-N 0.000 description 1
• IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
• OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
• FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
• BDKLKNJTMLIAFE-UHFFFAOYSA-N 2-(3-fluorophenyl)-1,3-oxazole-4-carbaldehyde Chemical compound FC1=CC=CC(C=2OC=C(C=O)N=2)=C1 BDKLKNJTMLIAFE-UHFFFAOYSA-N 0.000 description 1
• GUBGYTABKSRVRQ-UHFFFAOYSA-N 2-(hydroxymethyl)-6-[4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxane-3,4,5-triol Chemical compound OCC1OC(OC2C(O)C(O)C(O)OC2CO)C(O)C(O)C1O GUBGYTABKSRVRQ-UHFFFAOYSA-N 0.000 description 1
• LBLYYCQCTBFVLH-UHFFFAOYSA-M 2-methylbenzenesulfonate Chemical compound CC1=CC=CC=C1S([O-])(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-M 0.000 description 1
• WLAMNBDJUVNPJU-UHFFFAOYSA-N 2-methylbutyric acid Chemical compound CCC(C)C(O)=O WLAMNBDJUVNPJU-UHFFFAOYSA-N 0.000 description 1
• 229940080296 2-naphthalenesulfonate Drugs 0.000 description 1
• ZRPLANDPDWYOMZ-UHFFFAOYSA-N 3-cyclopentylpropionic acid Chemical compound OC(=O)CCC1CCCC1 ZRPLANDPDWYOMZ-UHFFFAOYSA-N 0.000 description 1
• XMIIGOLPHOKFCH-UHFFFAOYSA-M 3-phenylpropionate Chemical compound [O-]C(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-M 0.000 description 1
• MGWGWNFMUOTEHG-UHFFFAOYSA-N 4-(3,5-dimethylphenyl)-1,3-thiazol-2-amine Chemical compound CC1=CC(C)=CC(C=2N=C(N)SC=2)=C1 MGWGWNFMUOTEHG-UHFFFAOYSA-N 0.000 description 1
• 239000005541 ACE inhibitor Substances 0.000 description 1
• 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 1
• YCIPQJTZJGUXND-UHFFFAOYSA-N Aglaia odorata Alkaloid Natural products C1=CC(OC)=CC=C1C1(C(C=2C(=O)N3CCCC3=NC=22)C=3C=CC=CC=3)C2(O)C2=C(OC)C=C(OC)C=C2O1 YCIPQJTZJGUXND-UHFFFAOYSA-N 0.000 description 1
• 206010002383 Angina Pectoris Diseases 0.000 description 1
• 208000031104 Arterial Occlusive disease Diseases 0.000 description 1
• 200000000007 Arterial disease Diseases 0.000 description 1
• 241000416162 Astragalus gummifer Species 0.000 description 1
• 208000037260 Atherosclerotic Plaque Diseases 0.000 description 1
• 241000894006 Bacteria Species 0.000 description 1
• BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
• 201000006474 Brain Ischemia Diseases 0.000 description 1
• FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 1
• FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 1
• 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
• 206010008120 Cerebral ischaemia Diseases 0.000 description 1
• 229920001661 Chitosan Polymers 0.000 description 1
• 206010008909 Chronic Hepatitis Diseases 0.000 description 1
• KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
• 244000060011 Cocos nucifera Species 0.000 description 1
• 206010009900 Colitis ulcerative Diseases 0.000 description 1
• 208000029767 Congenital, Hereditary, and Neonatal Diseases and Abnormalities Diseases 0.000 description 1
• 208000011231 Crohn disease Diseases 0.000 description 1
• 229920000858 Cyclodextrin Polymers 0.000 description 1
• ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
• AEMOLEFTQBMNLQ-AQKNRBDQSA-N D-glucopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-AQKNRBDQSA-N 0.000 description 1
• YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 1
• FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
• BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
• QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical compound [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 description 1
• 206010052804 Drug tolerance Diseases 0.000 description 1
• IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
• CTKXFMQHOOWWEB-UHFFFAOYSA-N Ethylene oxide/propylene oxide copolymer Chemical compound CCCOC(C)COCCO CTKXFMQHOOWWEB-UHFFFAOYSA-N 0.000 description 1
• 229920003143 Eudragit® FS 30 D Polymers 0.000 description 1
• 229920003139 Eudragit® L 100 Polymers 0.000 description 1
• 229920003135 Eudragit® L 100-55 Polymers 0.000 description 1
• 229920003141 Eudragit® S 100 Polymers 0.000 description 1
• VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
• 206010018364 Glomerulonephritis Diseases 0.000 description 1
• 229920000084 Gum arabic Polymers 0.000 description 1
• 206010019280 Heart failures Diseases 0.000 description 1
• 241000282412 Homo Species 0.000 description 1
• VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
• UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
• CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
• 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
• 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
• WOBHKFSMXKNTIM-UHFFFAOYSA-N Hydroxyethyl methacrylate Chemical compound CC(=C)C(=O)OCCO WOBHKFSMXKNTIM-UHFFFAOYSA-N 0.000 description 1
• 229920001479 Hydroxyethyl methyl cellulose Polymers 0.000 description 1
• 206010020772 Hypertension Diseases 0.000 description 1
• 206010061218 Inflammation Diseases 0.000 description 1
• 206010022680 Intestinal ischaemia Diseases 0.000 description 1
• 208000005168 Intussusception Diseases 0.000 description 1
• 208000003456 Juvenile Arthritis Diseases 0.000 description 1
• 206010059176 Juvenile idiopathic arthritis Diseases 0.000 description 1
• CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
• FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
• JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
• 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
• 240000007472 Leucaena leucocephala Species 0.000 description 1
• WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
• OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 1
• GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
• CERQOIWHTDAKMF-UHFFFAOYSA-M Methacrylate Chemical compound CC(=C)C([O-])=O CERQOIWHTDAKMF-UHFFFAOYSA-M 0.000 description 1
• AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
• 229920003091 Methocel™ Polymers 0.000 description 1
• VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 1
• 229910002089 NOx Inorganic materials 0.000 description 1
• 206010029113 Neovascularisation Diseases 0.000 description 1
• PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
• YJTRMHYUGNFUAU-UHFFFAOYSA-H O.N(=O)[O-].[K+].[Co+2].O.O.N(=O)[O-].N(=O)[O-].[Co+2].[K+].N(=O)[O-].N(=O)[O-].N(=O)[O-] Chemical compound O.N(=O)[O-].[K+].[Co+2].O.O.N(=O)[O-].N(=O)[O-].[Co+2].[K+].N(=O)[O-].N(=O)[O-].N(=O)[O-] YJTRMHYUGNFUAU-UHFFFAOYSA-H 0.000 description 1
• QIGAGQKDGCHXDJ-UHFFFAOYSA-L O.O.O.N(=O)[O-].[Mg+2].N(=O)[O-] Chemical compound O.O.O.N(=O)[O-].[Mg+2].N(=O)[O-] QIGAGQKDGCHXDJ-UHFFFAOYSA-L 0.000 description 1
• MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
• 229910019142 PO4 Inorganic materials 0.000 description 1
• 208000018262 Peripheral vascular disease Diseases 0.000 description 1
• RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 1
• 229920000436 Poly(lactide-co-glycolide)-block-poly(ethylene glycol)-block-poly(lactide-co-glycolide) Polymers 0.000 description 1
• 229920000954 Polyglycolide Polymers 0.000 description 1
• XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
• GOOHAUXETOMSMM-UHFFFAOYSA-N Propylene oxide Chemical compound CC1CO1 GOOHAUXETOMSMM-UHFFFAOYSA-N 0.000 description 1
• 201000004681 Psoriasis Diseases 0.000 description 1
• 206010064911 Pulmonary arterial hypertension Diseases 0.000 description 1
• 208000003782 Raynaud disease Diseases 0.000 description 1
• 208000012322 Raynaud phenomenon Diseases 0.000 description 1
• 206010063837 Reperfusion injury Diseases 0.000 description 1
• 208000013616 Respiratory Distress Syndrome Diseases 0.000 description 1
• 235000004443 Ricinus communis Nutrition 0.000 description 1
• 206010040943 Skin Ulcer Diseases 0.000 description 1
• FKNQFGJONOIPTF-UHFFFAOYSA-N Sodium cation Chemical compound [Na+] FKNQFGJONOIPTF-UHFFFAOYSA-N 0.000 description 1
• QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
• 229940123464 Thiazolidinedione Drugs 0.000 description 1
• ZMZDMBWJUHKJPS-UHFFFAOYSA-M Thiocyanate anion Chemical compound [S-]C#N ZMZDMBWJUHKJPS-UHFFFAOYSA-M 0.000 description 1
• 208000007536 Thrombosis Diseases 0.000 description 1
• 208000026062 Tissue disease Diseases 0.000 description 1
• 229920001615 Tragacanth Polymers 0.000 description 1
• YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
• 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
• 201000006704 Ulcerative Colitis Diseases 0.000 description 1
• 206010046851 Uveitis Diseases 0.000 description 1
• 206010047163 Vasospasm Diseases 0.000 description 1
• 208000036142 Viral infection Diseases 0.000 description 1
• FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
• 229930003268 Vitamin C Natural products 0.000 description 1
• 229930003427 Vitamin E Natural products 0.000 description 1
• TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
• 230000002159 abnormal effect Effects 0.000 description 1
• 238000002835 absorbance Methods 0.000 description 1
• 235000010489 acacia gum Nutrition 0.000 description 1
• 239000000205 acacia gum Substances 0.000 description 1
• VJHCJDRQFCCTHL-UHFFFAOYSA-N acetic acid 2,3,4,5,6-pentahydroxyhexanal Chemical compound CC(O)=O.OCC(O)C(O)C(O)C(O)C=O VJHCJDRQFCCTHL-UHFFFAOYSA-N 0.000 description 1
• IZFOVFBRJMXESP-UHFFFAOYSA-N acetic acid;nitrous acid Chemical compound ON=O.CC(O)=O IZFOVFBRJMXESP-UHFFFAOYSA-N 0.000 description 1
• 239000011149 active material Substances 0.000 description 1
• 239000013543 active substance Substances 0.000 description 1
• 208000024716 acute asthma Diseases 0.000 description 1
• WNLRTRBMVRJNCN-UHFFFAOYSA-L adipate(2-) Chemical compound [O-]C(=O)CCCCC([O-])=O WNLRTRBMVRJNCN-UHFFFAOYSA-L 0.000 description 1
• 201000000028 adult respiratory distress syndrome Diseases 0.000 description 1
• 239000000443 aerosol Substances 0.000 description 1
• 238000013019 agitation Methods 0.000 description 1
• 229910052783 alkali metal Inorganic materials 0.000 description 1
• FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
• 208000026935 allergic disease Diseases 0.000 description 1
• 230000000172 allergic effect Effects 0.000 description 1
• SNAAJJQQZSMGQD-UHFFFAOYSA-N aluminum magnesium Chemical compound [Mg].[Al] SNAAJJQQZSMGQD-UHFFFAOYSA-N 0.000 description 1
• CAMXVZOXBADHNJ-UHFFFAOYSA-N ammonium nitrite Chemical compound [NH4+].[O-]N=O CAMXVZOXBADHNJ-UHFFFAOYSA-N 0.000 description 1
• 206010002022 amyloidosis Diseases 0.000 description 1
• 238000004458 analytical method Methods 0.000 description 1
• 210000000648 angioblast Anatomy 0.000 description 1
• 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 1
• 238000010171 animal model Methods 0.000 description 1
• 210000003423 ankle Anatomy 0.000 description 1
• 239000003242 anti bacterial agent Substances 0.000 description 1
• 230000003627 anti-cholesterol Effects 0.000 description 1
• 229940121363 anti-inflammatory agent Drugs 0.000 description 1
• 239000002260 anti-inflammatory agent Substances 0.000 description 1
• 230000002785 anti-thrombosis Effects 0.000 description 1
• 229940088710 antibiotic agent Drugs 0.000 description 1
• 239000003146 anticoagulant agent Substances 0.000 description 1
• 239000003472 antidiabetic agent Substances 0.000 description 1
• 229940125708 antidiabetic agent Drugs 0.000 description 1
• 239000003963 antioxidant agent Substances 0.000 description 1
• 235000006708 antioxidants Nutrition 0.000 description 1
• 229940127218 antiplatelet drug Drugs 0.000 description 1
• 208000021328 arterial occlusion Diseases 0.000 description 1
• 210000002565 arteriole Anatomy 0.000 description 1
• 208000011775 arteriosclerosis disease Diseases 0.000 description 1
• 229940072107 ascorbate Drugs 0.000 description 1
• 235000010323 ascorbic acid Nutrition 0.000 description 1
• 239000011668 ascorbic acid Substances 0.000 description 1
• 229940009098 aspartate Drugs 0.000 description 1
• 238000003556 assay Methods 0.000 description 1
• 230000003143 atherosclerotic effect Effects 0.000 description 1
• QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
• 208000010668 atopic eczema Diseases 0.000 description 1
• 229910052788 barium Inorganic materials 0.000 description 1
• DSAJWYNOEDNPEQ-UHFFFAOYSA-N barium atom Chemical compound [Ba] DSAJWYNOEDNPEQ-UHFFFAOYSA-N 0.000 description 1
• WOXYOIUNJIARCN-UHFFFAOYSA-L barium(2+);dinitrite;hydrate Chemical compound O.[Ba+2].[O-]N=O.[O-]N=O WOXYOIUNJIARCN-UHFFFAOYSA-L 0.000 description 1
• 239000002585 base Substances 0.000 description 1
• 210000002469 basement membrane Anatomy 0.000 description 1
• 235000013871 bee wax Nutrition 0.000 description 1
• 239000012166 beeswax Substances 0.000 description 1
• 229940077388 benzenesulfonate Drugs 0.000 description 1
• SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
• 229940050390 benzoate Drugs 0.000 description 1
• WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
• 229960002903 benzyl benzoate Drugs 0.000 description 1
• GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
• XMIIGOLPHOKFCH-UHFFFAOYSA-N beta-phenylpropanoic acid Natural products OC(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-N 0.000 description 1
• 239000000227 bioadhesive Substances 0.000 description 1
• 238000006065 biodegradation reaction Methods 0.000 description 1
• 229920001400 block copolymer Polymers 0.000 description 1
• 230000036765 blood level Effects 0.000 description 1
• 230000036772 blood pressure Effects 0.000 description 1
• 239000006172 buffering agent Substances 0.000 description 1
• 210000001217 buttock Anatomy 0.000 description 1
• 235000010216 calcium carbonate Nutrition 0.000 description 1
• FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
• 239000000378 calcium silicate Substances 0.000 description 1
• 229910052918 calcium silicate Inorganic materials 0.000 description 1
• 229960003340 calcium silicate Drugs 0.000 description 1
• 235000012241 calcium silicate Nutrition 0.000 description 1
• CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
• 235000013539 calcium stearate Nutrition 0.000 description 1
• 239000008116 calcium stearate Substances 0.000 description 1
• OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
• MIOPJNTWMNEORI-UHFFFAOYSA-N camphorsulfonic acid Chemical compound C1CC2(CS(O)(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-N 0.000 description 1
• 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
• 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
• 229940105329 carboxymethylcellulose Drugs 0.000 description 1
• 230000000747 cardiac effect Effects 0.000 description 1
• 231100001012 cardiac lesion Toxicity 0.000 description 1
• 235000010418 carrageenan Nutrition 0.000 description 1
• 229920001525 carrageenan Polymers 0.000 description 1
• 239000000679 carrageenan Substances 0.000 description 1
• 229940113118 carrageenan Drugs 0.000 description 1
• 239000000969 carrier Substances 0.000 description 1
• 239000004359 castor oil Substances 0.000 description 1
• 235000019438 castor oil Nutrition 0.000 description 1
• 230000015556 catabolic process Effects 0.000 description 1
• 150000001768 cations Chemical class 0.000 description 1
• 210000004027 cell Anatomy 0.000 description 1
• 230000030833 cell death Effects 0.000 description 1
• 230000006041 cell recruitment Effects 0.000 description 1
• 229950010118 cellacefate Drugs 0.000 description 1
• 230000001413 cellular effect Effects 0.000 description 1
• 210000001627 cerebral artery Anatomy 0.000 description 1
• 206010008118 cerebral infarction Diseases 0.000 description 1
• 238000002144 chemical decomposition reaction Methods 0.000 description 1
• 239000007910 chewable tablet Substances 0.000 description 1
• 229940045110 chitosan Drugs 0.000 description 1
• 208000019069 chronic childhood arthritis Diseases 0.000 description 1
• 201000005483 chronic intestinal vascular insufficiency Diseases 0.000 description 1
• 229960004588 cilostazol Drugs 0.000 description 1
• RRGUKTPIGVIEKM-UHFFFAOYSA-N cilostazol Chemical compound C=1C=C2NC(=O)CCC2=CC=1OCCCCC1=NN=NN1C1CCCCC1 RRGUKTPIGVIEKM-UHFFFAOYSA-N 0.000 description 1
• 208000024980 claudication Diseases 0.000 description 1
• 239000003240 coconut oil Substances 0.000 description 1
• 235000019864 coconut oil Nutrition 0.000 description 1
• 239000003086 colorant Substances 0.000 description 1
• 230000000052 comparative effect Effects 0.000 description 1
• 238000000748 compression moulding Methods 0.000 description 1
• 239000000599 controlled substance Substances 0.000 description 1
• 230000001276 controlling effect Effects 0.000 description 1
• 230000009519 contusion Effects 0.000 description 1
• 238000001816 cooling Methods 0.000 description 1
• 238000002586 coronary angiography Methods 0.000 description 1
• 230000002596 correlated effect Effects 0.000 description 1
• 235000012343 cottonseed oil Nutrition 0.000 description 1
• 239000002385 cottonseed oil Substances 0.000 description 1
• 239000006071 cream Substances 0.000 description 1
• 229960005168 croscarmellose Drugs 0.000 description 1
• 229960001681 croscarmellose sodium Drugs 0.000 description 1
• 229960000913 crospovidone Drugs 0.000 description 1
• 238000004132 cross linking Methods 0.000 description 1
• 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
• 239000001767 crosslinked sodium carboxy methyl cellulose Substances 0.000 description 1
• 239000013078 crystal Substances 0.000 description 1
• 238000002425 crystallisation Methods 0.000 description 1
• 230000008025 crystallization Effects 0.000 description 1
• 238000006731 degradation reaction Methods 0.000 description 1
• 230000001419 dependent effect Effects 0.000 description 1
• 230000008021 deposition Effects 0.000 description 1
• 229910052805 deuterium Inorganic materials 0.000 description 1
• 229960002086 dextran Drugs 0.000 description 1
• 239000008121 dextrose Substances 0.000 description 1
• 235000005911 diet Nutrition 0.000 description 1
• 230000000378 dietary effect Effects 0.000 description 1
• 235000020805 dietary restrictions Nutrition 0.000 description 1
• 238000010790 dilution Methods 0.000 description 1
• 239000012895 dilution Substances 0.000 description 1
• 229960002768 dipyridamole Drugs 0.000 description 1
• IZEKFCXSFNUWAM-UHFFFAOYSA-N dipyridamole Chemical compound C=12N=C(N(CCO)CCO)N=C(N3CCCCC3)C2=NC(N(CCO)CCO)=NC=1N1CCCCC1 IZEKFCXSFNUWAM-UHFFFAOYSA-N 0.000 description 1
• 239000007884 disintegrant Substances 0.000 description 1
• 239000002270 dispersing agent Substances 0.000 description 1
• 238000007922 dissolution test Methods 0.000 description 1
• GUVUOGQBMYCBQP-UHFFFAOYSA-N dmpu Chemical compound CN1CCCN(C)C1=O GUVUOGQBMYCBQP-UHFFFAOYSA-N 0.000 description 1
• POULHZVOKOAJMA-UHFFFAOYSA-M dodecanoate Chemical compound CCCCCCCCCCCC([O-])=O POULHZVOKOAJMA-UHFFFAOYSA-M 0.000 description 1
• 231100000673 dose–response relationship Toxicity 0.000 description 1
• 238000012377 drug delivery Methods 0.000 description 1
• 238000009510 drug design Methods 0.000 description 1
• 239000013583 drug formulation Substances 0.000 description 1
• 238000002651 drug therapy Methods 0.000 description 1
• 210000001198 duodenum Anatomy 0.000 description 1
• 239000000975 dye Substances 0.000 description 1
• 238000002592 echocardiography Methods 0.000 description 1
• 239000008157 edible vegetable oil Substances 0.000 description 1
• 230000013020 embryo development Effects 0.000 description 1
• 239000003974 emollient agent Substances 0.000 description 1
• 230000001804 emulsifying effect Effects 0.000 description 1
• 238000005516 engineering process Methods 0.000 description 1
• 230000006353 environmental stress Effects 0.000 description 1
• 230000002255 enzymatic effect Effects 0.000 description 1
• 230000003628 erosive effect Effects 0.000 description 1
• 150000002148 esters Chemical class 0.000 description 1
• CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
• 238000001704 evaporation Methods 0.000 description 1
• 230000008020 evaporation Effects 0.000 description 1
• 238000001125 extrusion Methods 0.000 description 1
• 229940125753 fibrate Drugs 0.000 description 1
• 210000002950 fibroblast Anatomy 0.000 description 1
• 238000011049 filling Methods 0.000 description 1
• 239000007888 film coating Substances 0.000 description 1
• 238000009501 film coating Methods 0.000 description 1
• 235000020375 flavoured syrup Nutrition 0.000 description 1
• NBVXSUQYWXRMNV-UHFFFAOYSA-N fluoromethane Chemical class FC NBVXSUQYWXRMNV-UHFFFAOYSA-N 0.000 description 1
• 239000003205 fragrance Substances 0.000 description 1
• 239000012458 free base Substances 0.000 description 1
• WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
• 210000004051 gastric juice Anatomy 0.000 description 1
• 238000001879 gelation Methods 0.000 description 1
• 239000007897 gelcap Substances 0.000 description 1
• 230000002068 genetic effect Effects 0.000 description 1
• 235000001727 glucose Nutrition 0.000 description 1
• 239000008103 glucose Substances 0.000 description 1
• 229940097042 glucuronate Drugs 0.000 description 1
• ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
• 229940074045 glyceryl distearate Drugs 0.000 description 1
• 229930182470 glycoside Natural products 0.000 description 1
• 150000002338 glycosides Chemical class 0.000 description 1
• 238000000227 grinding Methods 0.000 description 1
• 244000005709 gut microbiome Species 0.000 description 1
• 230000035876 healing Effects 0.000 description 1
• 230000036541 health Effects 0.000 description 1
• 210000002216 heart Anatomy 0.000 description 1
• 230000002440 hepatic effect Effects 0.000 description 1
• 208000006454 hepatitis Diseases 0.000 description 1
• FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
• 210000001624 hip Anatomy 0.000 description 1
• 239000003906 humectant Substances 0.000 description 1
• 150000004677 hydrates Chemical class 0.000 description 1
• 230000036571 hydration Effects 0.000 description 1
• 238000006703 hydration reaction Methods 0.000 description 1
• 239000000017 hydrogel Substances 0.000 description 1
• 239000001257 hydrogen Substances 0.000 description 1
• 229910052739 hydrogen Inorganic materials 0.000 description 1
• XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
• ZMZDMBWJUHKJPS-UHFFFAOYSA-N hydrogen thiocyanate Natural products SC#N ZMZDMBWJUHKJPS-UHFFFAOYSA-N 0.000 description 1
• 239000008172 hydrogenated vegetable oil Substances 0.000 description 1
• QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
• 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
• 229920000639 hydroxypropylmethylcellulose acetate succinate Polymers 0.000 description 1
• 230000001146 hypoxic effect Effects 0.000 description 1
• 229960003444 immunosuppressant agent Drugs 0.000 description 1
• 239000003018 immunosuppressive agent Substances 0.000 description 1
• 238000002513 implantation Methods 0.000 description 1
• 238000010874 in vitro model Methods 0.000 description 1
• 238000010952 in-situ formation Methods 0.000 description 1
• 238000011065 in-situ storage Methods 0.000 description 1
• 230000004054 inflammatory process Effects 0.000 description 1
• 238000001746 injection moulding Methods 0.000 description 1
• 239000000976 ink Substances 0.000 description 1
• 150000007529 inorganic bases Chemical class 0.000 description 1
• 238000001361 intraarterial administration Methods 0.000 description 1
• 238000007917 intracranial administration Methods 0.000 description 1
• 238000007918 intramuscular administration Methods 0.000 description 1
• 238000007912 intraperitoneal administration Methods 0.000 description 1
• 238000007914 intraventricular administration Methods 0.000 description 1
• 238000011835 investigation Methods 0.000 description 1
• 150000002500 ions Chemical class 0.000 description 1
• 230000007794 irritation Effects 0.000 description 1
• SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
• 210000004153 islets of langerhan Anatomy 0.000 description 1
• 238000002955 isolation Methods 0.000 description 1
• FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 1
• 201000002215 juvenile rheumatoid arthritis Diseases 0.000 description 1
• 210000003127 knee Anatomy 0.000 description 1
• 229940001447 lactate Drugs 0.000 description 1
• 229940099584 lactobionate Drugs 0.000 description 1
• JYTUSYBCFIZPBE-AMTLMPIISA-N lactobionic acid Chemical compound OC(=O)[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O JYTUSYBCFIZPBE-AMTLMPIISA-N 0.000 description 1
• 229940070765 laurate Drugs 0.000 description 1
• 210000003041 ligament Anatomy 0.000 description 1
• 230000000670 limiting effect Effects 0.000 description 1
• 239000002502 liposome Substances 0.000 description 1
• 239000011344 liquid material Substances 0.000 description 1
• 229940057995 liquid paraffin Drugs 0.000 description 1
• 239000006193 liquid solution Substances 0.000 description 1
• 239000006194 liquid suspension Substances 0.000 description 1
• 229910052744 lithium Inorganic materials 0.000 description 1
• IDNHOWMYUQKKTI-UHFFFAOYSA-M lithium nitrite Chemical compound [Li+].[O-]N=O IDNHOWMYUQKKTI-UHFFFAOYSA-M 0.000 description 1
• ZPLJFKAOGIWKGC-UHFFFAOYSA-M lithium;nitrite;hydrate Chemical compound [Li+].O.[O-]N=O ZPLJFKAOGIWKGC-UHFFFAOYSA-M 0.000 description 1
• 210000004185 liver Anatomy 0.000 description 1
• 239000006210 lotion Substances 0.000 description 1
• 210000003141 lower extremity Anatomy 0.000 description 1
• 210000003750 lower gastrointestinal tract Anatomy 0.000 description 1
• 230000001050 lubricating effect Effects 0.000 description 1
• 210000004072 lung Anatomy 0.000 description 1
• 206010025135 lupus erythematosus Diseases 0.000 description 1
• AAJBNRZDTJPMTJ-UHFFFAOYSA-L magnesium;dinitrite Chemical compound [Mg+2].[O-]N=O.[O-]N=O AAJBNRZDTJPMTJ-UHFFFAOYSA-L 0.000 description 1
• 238000002595 magnetic resonance imaging Methods 0.000 description 1
• 229940049920 malate Drugs 0.000 description 1
• VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
• BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
• 235000010449 maltitol Nutrition 0.000 description 1
• 239000000845 maltitol Substances 0.000 description 1
• VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
• 229940035436 maltitol Drugs 0.000 description 1
• 238000004519 manufacturing process Methods 0.000 description 1
• 210000004379 membrane Anatomy 0.000 description 1
• 239000012528 membrane Substances 0.000 description 1
• HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
• 230000002503 metabolic effect Effects 0.000 description 1
• 230000037323 metabolic rate Effects 0.000 description 1
• 229910000000 metal hydroxide Inorganic materials 0.000 description 1
• 150000004692 metal hydroxides Chemical class 0.000 description 1
• 229920003145 methacrylic acid copolymer Polymers 0.000 description 1
• 229930182817 methionine Natural products 0.000 description 1
• 235000006109 methionine Nutrition 0.000 description 1
• NXMXPVQZFYYPGD-UHFFFAOYSA-N methyl 2-methylprop-2-enoate;methyl prop-2-enoate Chemical compound COC(=O)C=C.COC(=O)C(C)=C NXMXPVQZFYYPGD-UHFFFAOYSA-N 0.000 description 1
• 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
• 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
• 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
• 229960002216 methylparaben Drugs 0.000 description 1
• 239000003094 microcapsule Substances 0.000 description 1
• 239000002480 mineral oil Substances 0.000 description 1
• 235000010446 mineral oil Nutrition 0.000 description 1
• 150000007522 mineralic acids Chemical class 0.000 description 1
• 239000004570 mortar (masonry) Substances 0.000 description 1
• 210000004877 mucosa Anatomy 0.000 description 1
• 201000006417 multiple sclerosis Diseases 0.000 description 1
• QNILTEGFHQSKFF-UHFFFAOYSA-N n-propan-2-ylprop-2-enamide Chemical compound CC(C)NC(=O)C=C QNILTEGFHQSKFF-UHFFFAOYSA-N 0.000 description 1
• 239000002105 nanoparticle Substances 0.000 description 1
• KVBGVZZKJNLNJU-UHFFFAOYSA-M naphthalene-2-sulfonate Chemical compound C1=CC=CC2=CC(S(=O)(=O)[O-])=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-M 0.000 description 1
• 201000001119 neuropathy Diseases 0.000 description 1
• 230000007823 neuropathy Effects 0.000 description 1
• 230000007935 neutral effect Effects 0.000 description 1
• 235000001968 nicotinic acid Nutrition 0.000 description 1
• 239000011664 nicotinic acid Substances 0.000 description 1
• 229910052757 nitrogen Inorganic materials 0.000 description 1
• JCXJVPUVTGWSNB-UHFFFAOYSA-N nitrogen dioxide Inorganic materials O=[N]=O JCXJVPUVTGWSNB-UHFFFAOYSA-N 0.000 description 1
• 150000004005 nitrosamines Chemical class 0.000 description 1
• 231100000862 numbness Toxicity 0.000 description 1
• 235000016709 nutrition Nutrition 0.000 description 1
• 239000007764 o/w emulsion Substances 0.000 description 1
• 239000002674 ointment Substances 0.000 description 1
• 229940049964 oleate Drugs 0.000 description 1
• ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
• 239000004006 olive oil Substances 0.000 description 1
• 235000008390 olive oil Nutrition 0.000 description 1
• 238000005457 optimization Methods 0.000 description 1
• 229940126701 oral medication Drugs 0.000 description 1
• 150000007524 organic acids Chemical class 0.000 description 1
• 150000007530 organic bases Chemical class 0.000 description 1
• 239000003960 organic solvent Substances 0.000 description 1
• 201000008482 osteoarthritis Diseases 0.000 description 1
• 230000036542 oxidative stress Effects 0.000 description 1
• 239000001301 oxygen Substances 0.000 description 1
• 229910052760 oxygen Inorganic materials 0.000 description 1
• 230000036284 oxygen consumption Effects 0.000 description 1
• 238000007911 parenteral administration Methods 0.000 description 1
• 230000037361 pathway Effects 0.000 description 1
• 235000010987 pectin Nutrition 0.000 description 1
• 229920001277 pectin Polymers 0.000 description 1
• 239000001814 pectin Substances 0.000 description 1
• 229960000292 pectin Drugs 0.000 description 1
• 208000030613 peripheral artery disease Diseases 0.000 description 1
• 230000035699 permeability Effects 0.000 description 1
• JRKICGRDRMAZLK-UHFFFAOYSA-L peroxydisulfate Chemical compound [O-]S(=O)(=O)OOS([O-])(=O)=O JRKICGRDRMAZLK-UHFFFAOYSA-L 0.000 description 1
• 239000008177 pharmaceutical agent Substances 0.000 description 1
• 239000000825 pharmaceutical preparation Substances 0.000 description 1
• 238000005191 phase separation Methods 0.000 description 1
• WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
• 235000021317 phosphate Nutrition 0.000 description 1
• NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
• 239000010452 phosphate Substances 0.000 description 1
• XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 description 1
• 208000024335 physical disease Diseases 0.000 description 1
• 230000035790 physiological processes and functions Effects 0.000 description 1
• 229940075930 picrate Drugs 0.000 description 1
• OXNIZHLAWKMVMX-UHFFFAOYSA-M picrate anion Chemical compound [O-]C1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-M 0.000 description 1
• 229950010765 pivalate Drugs 0.000 description 1
• 239000000106 platelet aggregation inhibitor Substances 0.000 description 1
• 229920001983 poloxamer Polymers 0.000 description 1
• 229920001993 poloxamer 188 Polymers 0.000 description 1
• 229940044519 poloxamer 188 Drugs 0.000 description 1
• 229920001992 poloxamer 407 Polymers 0.000 description 1
• 229940044476 poloxamer 407 Drugs 0.000 description 1
• 229920001432 poly(L-lactide) Polymers 0.000 description 1
• 229920000747 poly(lactic acid) Polymers 0.000 description 1
• 229920002627 poly(phosphazenes) Polymers 0.000 description 1
• 229920000728 polyester Polymers 0.000 description 1
• 229920000193 polymethacrylate Polymers 0.000 description 1
• 229920001184 polypeptide Polymers 0.000 description 1
• 229920001282 polysaccharide Polymers 0.000 description 1
• 239000005017 polysaccharide Substances 0.000 description 1
• 150000004804 polysaccharides Chemical class 0.000 description 1
• 229920001296 polysiloxane Polymers 0.000 description 1
• 229920002689 polyvinyl acetate Polymers 0.000 description 1
• 239000011118 polyvinyl acetate Substances 0.000 description 1
• 229940100467 polyvinyl acetate phthalate Drugs 0.000 description 1
• 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 1
• 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 1
• 239000011148 porous material Substances 0.000 description 1
• 238000002600 positron emission tomography Methods 0.000 description 1
• 230000002064 post-exposure prophylaxis Effects 0.000 description 1
• CJLBUPPBSFCQDN-UHFFFAOYSA-J potassium;cobalt(3+);tetranitrite Chemical compound [K+].[Co+3].[O-]N=O.[O-]N=O.[O-]N=O.[O-]N=O CJLBUPPBSFCQDN-UHFFFAOYSA-J 0.000 description 1
• 231100000175 potential carcinogenicity Toxicity 0.000 description 1
• 229940069328 povidone Drugs 0.000 description 1
• 238000001556 precipitation Methods 0.000 description 1
• 230000003449 preventive effect Effects 0.000 description 1
• 238000007639 printing Methods 0.000 description 1
• 102000004196 processed proteins & peptides Human genes 0.000 description 1
• 108090000765 processed proteins & peptides Proteins 0.000 description 1
• 230000000750 progressive effect Effects 0.000 description 1
• 230000000069 prophylactic effect Effects 0.000 description 1
• LZFIOSVZIQOVFW-UHFFFAOYSA-N propyl 2-hydroxybenzoate Chemical class CCCOC(=O)C1=CC=CC=C1O LZFIOSVZIQOVFW-UHFFFAOYSA-N 0.000 description 1
• 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
• 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
• 229960003415 propylparaben Drugs 0.000 description 1
• 235000018102 proteins Nutrition 0.000 description 1
• 108090000623 proteins and genes Proteins 0.000 description 1
• 102000004169 proteins and genes Human genes 0.000 description 1
• 230000002685 pulmonary effect Effects 0.000 description 1
• 208000002815 pulmonary hypertension Diseases 0.000 description 1
• 230000000541 pulsatile effect Effects 0.000 description 1
• 238000000746 purification Methods 0.000 description 1
• VTGOHKSTWXHQJK-UHFFFAOYSA-N pyrimidin-2-ol Chemical compound OC1=NC=CC=N1 VTGOHKSTWXHQJK-UHFFFAOYSA-N 0.000 description 1
• HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 description 1
• 239000010453 quartz Substances 0.000 description 1
• 125000001453 quaternary ammonium group Chemical group 0.000 description 1
• 230000005855 radiation Effects 0.000 description 1
• 150000003254 radicals Chemical class 0.000 description 1
• 230000002285 radioactive effect Effects 0.000 description 1
• 238000001959 radiotherapy Methods 0.000 description 1
• 238000001953 recrystallisation Methods 0.000 description 1
• 230000000306 recurrent effect Effects 0.000 description 1
• 230000002829 reductive effect Effects 0.000 description 1
• 230000001105 regulatory effect Effects 0.000 description 1
• 230000003252 repetitive effect Effects 0.000 description 1
• 230000035440 response to pH Effects 0.000 description 1
• 230000000979 retarding effect Effects 0.000 description 1
• 235000019172 retinyl palmitate Nutrition 0.000 description 1
• 239000011769 retinyl palmitate Substances 0.000 description 1
• 229940108325 retinyl palmitate Drugs 0.000 description 1
• 230000000250 revascularization Effects 0.000 description 1
• 238000012552 review Methods 0.000 description 1
• 206010039073 rheumatoid arthritis Diseases 0.000 description 1
• VPMVPQJJBGXJAI-UHFFFAOYSA-M rubidium(1+);nitrite Chemical compound [Rb+].[O-]N=O VPMVPQJJBGXJAI-UHFFFAOYSA-M 0.000 description 1
• 230000037390 scarring Effects 0.000 description 1
• HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
• 239000012056 semi-solid material Substances 0.000 description 1
• 239000008159 sesame oil Substances 0.000 description 1
• 235000011803 sesame oil Nutrition 0.000 description 1
• 230000007781 signaling event Effects 0.000 description 1
• KKKDGYXNGYJJRX-UHFFFAOYSA-M silver nitrite Chemical compound [Ag+].[O-]N=O KKKDGYXNGYJJRX-UHFFFAOYSA-M 0.000 description 1
• 210000005123 simple squamous epithelium Anatomy 0.000 description 1
• 238000004088 simulation Methods 0.000 description 1
• 231100000019 skin ulcer Toxicity 0.000 description 1
• 210000000329 smooth muscle myocyte Anatomy 0.000 description 1
• 229940087562 sodium acetate trihydrate Drugs 0.000 description 1
• 235000010413 sodium alginate Nutrition 0.000 description 1
• 239000000661 sodium alginate Substances 0.000 description 1
• 229940005550 sodium alginate Drugs 0.000 description 1
• 235000017557 sodium bicarbonate Nutrition 0.000 description 1
• 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
• 229910001467 sodium calcium phosphate Inorganic materials 0.000 description 1
• 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
• 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
• 229910001415 sodium ion Inorganic materials 0.000 description 1
• 239000001488 sodium phosphate Substances 0.000 description 1
• 229940080313 sodium starch Drugs 0.000 description 1
• 210000004872 soft tissue Anatomy 0.000 description 1
• 239000007909 solid dosage form Substances 0.000 description 1
• 239000011343 solid material Substances 0.000 description 1
• 239000008247 solid mixture Substances 0.000 description 1
• 238000007711 solidification Methods 0.000 description 1
• 230000008023 solidification Effects 0.000 description 1
• 239000002594 sorbent Substances 0.000 description 1
• 229960002920 sorbitol Drugs 0.000 description 1
• 239000012798 spherical particle Substances 0.000 description 1
• 230000007480 spreading Effects 0.000 description 1
• 238000003892 spreading Methods 0.000 description 1
• 239000007858 starting material Substances 0.000 description 1
• 210000000130 stem cell Anatomy 0.000 description 1
• 239000008174 sterile solution Substances 0.000 description 1
• 238000007920 subcutaneous administration Methods 0.000 description 1
• KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
• 235000000346 sugar Nutrition 0.000 description 1
• 238000009495 sugar coating Methods 0.000 description 1
• 229910052717 sulfur Inorganic materials 0.000 description 1
• 239000000829 suppository Substances 0.000 description 1
• 230000002459 sustained effect Effects 0.000 description 1
• 230000008961 swelling Effects 0.000 description 1
• 238000003786 synthesis reaction Methods 0.000 description 1
• 230000009885 systemic effect Effects 0.000 description 1
• 229940095064 tartrate Drugs 0.000 description 1
• 210000002435 tendon Anatomy 0.000 description 1
• 238000010998 test method Methods 0.000 description 1
• CBXCPBUEXACCNR-UHFFFAOYSA-N tetraethylammonium Chemical compound CC[N+](CC)(CC)CC CBXCPBUEXACCNR-UHFFFAOYSA-N 0.000 description 1
• QEMXHQIAXOOASZ-UHFFFAOYSA-N tetramethylammonium Chemical compound C[N+](C)(C)C QEMXHQIAXOOASZ-UHFFFAOYSA-N 0.000 description 1
• 238000011285 therapeutic regimen Methods 0.000 description 1
• 238000005979 thermal decomposition reaction Methods 0.000 description 1
• 229920001169 thermoplastic Polymers 0.000 description 1
• 239000004416 thermosoftening plastic Substances 0.000 description 1
• ICRHORQIUXBEPA-UHFFFAOYSA-N thionitrous acid Chemical compound SN=O ICRHORQIUXBEPA-UHFFFAOYSA-N 0.000 description 1
• 230000003867 tiredness Effects 0.000 description 1
• 208000016255 tiredness Diseases 0.000 description 1
• 208000037816 tissue injury Diseases 0.000 description 1
• 239000004408 titanium dioxide Substances 0.000 description 1
• 238000011200 topical administration Methods 0.000 description 1
• 230000000699 topical effect Effects 0.000 description 1
• 231100000331 toxic Toxicity 0.000 description 1
• 230000002588 toxic effect Effects 0.000 description 1
• 235000010487 tragacanth Nutrition 0.000 description 1
• 239000000196 tragacanth Substances 0.000 description 1
• 229940116362 tragacanth Drugs 0.000 description 1
• 230000009466 transformation Effects 0.000 description 1
• 230000007704 transition Effects 0.000 description 1
• 150000004684 trihydrates Chemical class 0.000 description 1
• 125000005591 trimellitate group Chemical group 0.000 description 1
• RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
• 229910052722 tritium Inorganic materials 0.000 description 1
• 238000002604 ultrasonography Methods 0.000 description 1
• ZDPHROOEEOARMN-UHFFFAOYSA-N undecanoic acid Chemical compound CCCCCCCCCCC(O)=O ZDPHROOEEOARMN-UHFFFAOYSA-N 0.000 description 1
• 238000009827 uniform distribution Methods 0.000 description 1
• 210000000689 upper leg Anatomy 0.000 description 1
• 238000011144 upstream manufacturing Methods 0.000 description 1
• NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical class CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 1
• 208000019553 vascular disease Diseases 0.000 description 1
• 230000004862 vasculogenesis Effects 0.000 description 1
• 230000024883 vasodilation Effects 0.000 description 1
• 229940124549 vasodilator Drugs 0.000 description 1
• 239000003071 vasodilator agent Substances 0.000 description 1
• 210000003462 vein Anatomy 0.000 description 1
• 230000007998 vessel formation Effects 0.000 description 1
• 230000009385 viral infection Effects 0.000 description 1
• 235000019155 vitamin A Nutrition 0.000 description 1
• 239000011719 vitamin A Substances 0.000 description 1
• 235000019154 vitamin C Nutrition 0.000 description 1
• 239000011718 vitamin C Substances 0.000 description 1
• 235000019165 vitamin E Nutrition 0.000 description 1
• 229940046009 vitamin E Drugs 0.000 description 1
• 239000011709 vitamin E Substances 0.000 description 1
• 229940045997 vitamin a Drugs 0.000 description 1
• 239000003643 water by type Substances 0.000 description 1
• 239000001993 wax Substances 0.000 description 1
• 230000003442 weekly effect Effects 0.000 description 1
• 230000004584 weight gain Effects 0.000 description 1
• 235000019786 weight gain Nutrition 0.000 description 1
• 239000000080 wetting agent Substances 0.000 description 1
• 229920001285 xanthan gum Polymers 0.000 description 1
• 235000010493 xanthan gum Nutrition 0.000 description 1
• 239000000230 xanthan gum Substances 0.000 description 1
• 229940082509 xanthan gum Drugs 0.000 description 1
• 239000000811 xylitol Substances 0.000 description 1
• 235000010447 xylitol Nutrition 0.000 description 1
• HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
• 229960002675 xylitol Drugs 0.000 description 1
• 239000011701 zinc Substances 0.000 description 1
• XOOUIPVCVHRTMJ-UHFFFAOYSA-L zinc stearate Chemical compound [Zn+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O XOOUIPVCVHRTMJ-UHFFFAOYSA-L 0.000 description 1
• UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1
• HHIMNFJHTNVXBJ-UHFFFAOYSA-L zinc;dinitrite Chemical compound [Zn+2].[O-]N=O.[O-]N=O HHIMNFJHTNVXBJ-UHFFFAOYSA-L 0.000 description 1